Artificial MicroRNA-Mediated Tgfbr2 and Pdgfrb Co-Silencing Ameliorates Carbon Tetrachloride–Induced Hepatic Fibrosis in Mice
Authors:
- 8 February 2019
- journal article
- research article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 30 (2) , 179-196
Abstract
Hepatic stellate cells (HSCs) are the primary cell type responsible for liver fibrogenesis. Transforming growth factor beta 1 (TGF-β1) and platelet-derived growth factor (PDGF) are key profibrotic cytokines that regulate HSC activation and proliferation with functional convergence. Dual RNA interference against their receptors may achieve therapeutic effects. A novel RNAi strategy based on HSC-specific GFAP promoter-driven and lentiviral-expressed artificial microRNAs (amiRNAs) was devised that consists of an microRNA-30a backbone and effective shRNAs against mouse Pdgfrβ and Tgfbr2 . Then, its antifibrotic efficacy was tested in primary and cultured HSCs and in mice affected with carbon tetrachloride–induced hepatic fibrosis. The study shows that amiRNA-mediated Pdgfrβ and Tgfbr2 co-silencing inhibits HSC activation and proliferation. After recombinant lentiviral particles were delivered into the liver via tail-vein injection, therapeutic amiRNAs were preferentially expressed in HSCs and efficiently co-knocked down in situ Tgfbr2 and Pdgfrβ expression, which correlates with downregulated expression of target or effector genes of their signaling, which include Pai-1 , P70S6K , and D-cyclins . amiRNA-based HSC-specific co-silencing of Tgfbr2 and Pdgfrβ significantly suppressed hepatic expression of fibrotic markers α-Sma and Col1a1, extracellular matrix regulators Mmps and Timp1, and phenotypically ameliorated liver fibrosis, as indicated by reductions in serum alanine aminotransferase activity, collagen deposition, and α-Sma-positive staining. The findings provide proof of concept for the use of amiRNA-mediated co-silencing of two profibrogenic pathways in liver fibrosis treatment and highlight the therapeutic potential of concatenated amiRNAs for gene therapy.Keywords
This publication has 82 references indexed in Scilit:
- The Loop Position of shRNAs and Pre-miRNAs Is Critical for the Accuracy of Dicer Processing In VivoCell, 2012
- PAI‐1 in tissue fibrosisJournal of Cellular Physiology, 2011
- Antifibrotic Effect of MMP13-encoding Plasmid DNA Delivered Using Polyethylenimine Shielded With Hyaluronic AcidMolecular Therapy, 2011
- Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAiNature Biotechnology, 2011
- MeCP2 Controls an Epigenetic Pathway That Promotes Myofibroblast Transdifferentiation and FibrosisGastroenterology, 2010
- Inhibition of phosphatidylinositol 3-kinase signaling in hepatic stellate cells blocks the progression of hepatic fibrosis #Hepatology, 2009
- Therapeutic targeting of the PDGF and TGF-β-signaling pathways in hepatic stellate cells by PTK787/ZK22258Laboratory Investigation, 2009
- Artificial MicroRNAs as siRNA Shuttles: Improved Safety as Compared to shRNAs In vitro and In vivoMolecular Therapy, 2009
- Sustained suppression of Bcr-Abl-driven lymphoid leukemia by microRNA mimicsProceedings of the National Academy of Sciences, 2007
- Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathwaysNature, 2006